YAP/Hippo Pathway and Cancer Immunity: It Takes Two to Tango

Hippo pathway with its main molecule YAP is a crucial pathway for development, tissue homeostasis, wound healing, tissue regeneration, and cancer. In this review, we discuss the multiple effects of the YAP/Hippo pathway in the immune system and cancer. We analyzed a series of effects: extracellular vesicles enhanced immunity through inhibition of LATS1/2, ways of modulation of the tumor microenvironment, YAP- and TAZ-mediated upregulation of PDL1, high expression of YAP and PDL1 in EGFR-TKI-resistant cells, enhanced YAP activity in inflammation, and the effect of the Hippo pathway on T cells, B cells, Tregs, macrophages, and myeloid-derived suppressor cells (MDSCs). These pleiotropic effects render the YAP and Hippo pathway a key pathway for exploitation in the future, in order to enhance our immunotherapy treatment strategies in oncology.

[1]  Jinying Wei,et al.  miR-21 regulates immunosuppression mediated by myeloid-derived suppressor cells by impairing RUNX1-YAP interaction in lung cancer , 2020, Cancer cell international.

[2]  A. Bouchard,et al.  Hippo Signal Transduction Mechanisms in T Cell Immunity , 2020, Immune network.

[3]  Pinglong Xu,et al.  The Hippo Pathway in Innate Anti-microbial Immunity and Anti-tumor Immunity , 2020, Frontiers in Immunology.

[4]  T. Kinashi,et al.  MST1/2 Balance Immune Activation and Tolerance by Orchestrating Adhesion, Transcription, and Organelle Dynamics in Lymphocytes , 2020, Frontiers in Immunology.

[5]  A. Pobbati,et al.  A combat with the YAP/TAZ-TEAD oncoproteins for cancer therapy , 2020, Theranostics.

[6]  Jun Li,et al.  Symbiotic Macrophage-Glioma Cell Interactions Reveal Synthetic Lethality in PTEN-Null Glioma. , 2019, Cancer cell.

[7]  Han-Chow Wang,et al.  Extracellular vesicles secreted by hypoxia pre-challenged mesenchymal stem cells promote non-small cell lung cancer cell growth and mobility as well as macrophage M2 polarization via miR-21-5p delivery , 2019, Journal of experimental & clinical cancer research : CR.

[8]  H. Sugiyama,et al.  Molecular Characteristics of DNA-Alkylating PI Polyamides Targeting RUNX Transcription Factors. , 2019, Journal of the American Chemical Society.

[9]  Randy L. Johnson,et al.  The signaling protein Wnt5a promotes TGFβ1-mediated macrophage polarization and kidney fibrosis by inducing the transcriptional regulators Yap/Taz , 2018, The Journal of Biological Chemistry.

[10]  C. Fan,et al.  Cdh1 and Pik3ca Mutations Cooperate to Induce Immune-Related Invasive Lobular Carcinoma of the Breast , 2018, Cell reports.

[11]  H. Arima,et al.  B cells with aberrant activation of Notch1 signaling promote Treg and Th2 cell-dominant T-cell responses via IL-33. , 2018, Blood advances.

[12]  M. Machner,et al.  The Legionella Effector Kinase LegK7 Hijacks the Host Hippo Pathway to Promote Infection. , 2018, Cell host & microbe.

[13]  Y. Nie,et al.  Inhibition of YAP reverses primary resistance to EGFR inhibitors in colorectal cancer cells. , 2018, Oncology reports.

[14]  Zhiguang Li,et al.  YAP Is Essential for Treg-Mediated Suppression of Antitumor Immunity. , 2018, Cancer discovery.

[15]  Xiao-shi Zhang,et al.  Tumour YAP1 and PTEN expression correlates with tumour‐associated myeloid suppressor cell expansion and reduced survival in colorectal cancer , 2018, Immunology.

[16]  Su-Jae Lee,et al.  SPON2 Promotes M1-like Macrophage Recruitment and Inhibits Hepatocellular Carcinoma Metastasis by Distinct Integrin-Rho GTPase-Hippo Pathways. , 2018, Cancer research.

[17]  Xiaolong Yang,et al.  The Hippo Pathway: Immunity and Cancer , 2018, Cancers.

[18]  Cheng-Ta Yang,et al.  Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma , 2018, Journal of cellular and molecular medicine.

[19]  P. Khanal,et al.  The Hippo Pathway Component TAZ Promotes Immune Evasion in Human Cancer through PD-L1. , 2018, Cancer research.

[20]  K. Guan,et al.  Deregulation and Therapeutic Potential of the Hippo Pathway in Cancer , 2018 .

[21]  Christian N. Cunningham,et al.  Targeting the Hippo Pathway and Cancer through the TEAD Family of Transcription Factors , 2018, Cancers.

[22]  T. Tan,et al.  RUNX1 and RUNX3 protect against YAP-mediated EMT, stem-ness and shorter survival outcomes in breast cancer , 2018, Oncotarget.

[23]  Matija Snuderl,et al.  Hacking macrophage-associated immunosuppression for regulating glioblastoma angiogenesis. , 2018, Biomaterials.

[24]  E. Shin,et al.  YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma , 2018, Cancer Immunology Research.

[25]  Cheng-Wen Wu,et al.  Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas , 2018, Scientific Reports.

[26]  F. Bailly,et al.  Targeting Transcriptional Enhanced Associate Domains (TEADs). , 2017, Journal of medicinal chemistry.

[27]  Hue Lee,et al.  PD-L1 confers resistance to EGFR mutation-independent tyrosine kinase inhibitors in non-small cell lung cancer via upregulation of YAP1 expression , 2017, Oncotarget.

[28]  Sang Yeon Cho,et al.  Hippo effector YAP directly regulates the expression of PD-L1 transcripts in EGFR-TKI-resistant lung adenocarcinoma. , 2017, Biochemical and biophysical research communications.

[29]  Yuchen Liu,et al.  Hepatic Hippo signaling inhibits protumoural microenvironment to suppress hepatocellular carcinoma , 2017, Gut.

[30]  Xuexiang Han,et al.  A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer. , 2017, Cancer letters.

[31]  L. Chin,et al.  PRKCI promotes immune suppression in ovarian cancer , 2017, Genes & development.

[32]  Jiahuai Han,et al.  The transcriptional coactivator TAZ regulates reciprocal differentiation of TH17 cells and Treg cells , 2017, Nature Immunology.

[33]  J. Rao,et al.  YAP-1 Promotes Tregs Differentiation in Hepatocellular Carcinoma by Enhancing TGFBR2 Transcription , 2017, Cellular Physiology and Biochemistry.

[34]  Alissa M. Weaver,et al.  Extracellular Vesicles: Unique Intercellular Delivery Vehicles. , 2017, Trends in cell biology.

[35]  Y. Yen,et al.  Ovatodiolide suppresses colon tumorigenesis and prevents polarization of M2 tumor-associated macrophages through YAP oncogenic pathways , 2017, Journal of Hematology & Oncology.

[36]  Hongyang Wang,et al.  Single tumor-initiating cells evade immune clearance by recruiting type II macrophages , 2017, Genes & development.

[37]  G. Natoli,et al.  A shortcut for early macrophage recruitment into tumors by activated oncogenes. , 2017, Genes & development.

[38]  C. Datz,et al.  YAP–IL-6ST autoregulatory loop activated on APC loss controls colonic tumorigenesis , 2017, Proceedings of the National Academy of Sciences.

[39]  W. Tao,et al.  Mst1 positively regulates B-cell receptor signaling via CD19 transcriptional levels. , 2016, Blood advances.

[40]  Matthew V. Holt,et al.  The Hippo Pathway Kinases LATS1/2 Suppress Cancer Immunity , 2016, Cell.

[41]  Qiaojun He,et al.  Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells , 2016, Scientific Reports.

[42]  Shannon M. White,et al.  Yes-Associated Protein Mediates Immune Reprogramming in Pancreatic Ductal Adenocarcinoma , 2016, Oncogene.

[43]  Yeon-Hee Park,et al.  Hippo pathway effector YAP inhibition restores the sensitivity of EGFR-TKI in lung adenocarcinoma having primary or acquired EGFR-TKI resistance. , 2016, Biochemical and biophysical research communications.

[44]  A. Fields,et al.  PKCι regulates nuclear YAP1 localization and ovarian cancer tumorigenesis , 2016, Oncogene.

[45]  L. Mariani,et al.  Analysis of the hippo transducers TAZ and YAP in cervical cancer and its microenvironment , 2016, Oncoimmunology.

[46]  T. Kinashi,et al.  Enhanced cytotoxic T‐cell function and inhibition of tumor progression by Mst1 deficiency , 2016, FEBS letters.

[47]  Valerie M. Weaver,et al.  Microenvironment rigidity modulates responses to the HER2 receptor tyrosine kinase inhibitor lapatinib via YAP and TAZ transcription factors , 2015, Molecular biology of the cell.

[48]  G. G. Galli,et al.  YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers. , 2015, Molecular cell.

[49]  Antonio Rosato,et al.  Genome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth , 2015, Nature Cell Biology.

[50]  I. Clay,et al.  YAP1 Exerts Its Transcriptional Control via TEAD-Mediated Activation of Enhancers , 2015, PLoS genetics.

[51]  W. Garrett,et al.  CCL2 Promotes Colorectal Carcinogenesis by Enhancing Polymorphonuclear Myeloid-Derived Suppressor Cell Population and Function , 2015, Cell reports.

[52]  Yasufumi Yamamoto,et al.  Small molecules inhibiting the nuclear localization of YAP/TAZ for chemotherapeutics and chemosensitizers against breast cancers , 2015, FEBS open bio.

[53]  Molly M Stevens,et al.  Cell-derived vesicles for drug therapy and diagnostics: opportunities and challenges. , 2015, Nano today.

[54]  A. Sikorski,et al.  The effect of statins on cancer cells—review , 2015, Tumor Biology.

[55]  Fumito Ito,et al.  Antitumor effector B cells directly kill tumor cells via the Fas/FasL pathway and are regulated by IL‐10 , 2015, European journal of immunology.

[56]  Jiang Li,et al.  Tumor-induced myeloid-derived suppressor cells promote tumor progression through oxidative metabolism in human colorectal cancer , 2015, Journal of Translational Medicine.

[57]  S. Mehrotra,et al.  Th17 Cells in Cancer: The Ultimate Identity Crisis , 2014, Front. Immunol..

[58]  G. Tonon,et al.  RESCUE OF HIPPO CO-ACTIVATOR YAP1 TRIGGERS DNA DAMAGE-INDUCED APOPTOSIS IN HEMATOLOGICAL CANCERS , 2014, Nature Medicine.

[59]  A. Rosato,et al.  Metabolic control of YAP and TAZ by the mevalonate pathway , 2014, Nature Cell Biology.

[60]  B. Mao,et al.  SIRT1 regulates YAP2-mediated cell proliferation and chemoresistance in hepatocellular carcinoma , 2014, Oncogene.

[61]  H. Ji,et al.  A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer. , 2014, Cancer cell.

[62]  J. Talmadge,et al.  History of myeloid-derived suppressor cells , 2013, Nature Reviews Cancer.

[63]  Yusuke Yoshioka,et al.  Neutral Sphingomyelinase 2 (nSMase2)-dependent Exosomal Transfer of Angiogenic MicroRNAs Regulate Cancer Cell Metastasis , 2013, The Journal of Biological Chemistry.

[64]  A. Pobbati,et al.  Emerging roles of TEAD transcription factors and its coactivators in cancers , 2013, Cancer biology & therapy.

[65]  U. Syrbe,et al.  TNF signaling drives myeloid-derived suppressor cell accumulation. , 2012, The Journal of clinical investigation.

[66]  R. Palmqvist,et al.  The Distribution of Macrophages with a M1 or M2 Phenotype in Relation to Prognosis and the Molecular Characteristics of Colorectal Cancer , 2012, PloS one.

[67]  A. Pobbati,et al.  Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes. , 2012, Structure.

[68]  Jun O. Liu,et al.  Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP. , 2012, Genes & development.

[69]  Y. Hata,et al.  A Novel Acetylation Cycle of Transcription Co-activator Yes-associated Protein That Is Downstream of Hippo Pathway Is Triggered in Response to SN2 Alkylating Agents* , 2012, The Journal of Biological Chemistry.

[70]  Qingsheng Li,et al.  Transcription factor Foxo1 represses T-bet-mediated effector functions and promotes memory CD8(+) T cell differentiation. , 2012, Immunity.

[71]  A. Mantovani,et al.  The growing diversity and spectrum of action of myeloid‐derived suppressor cells , 2010, European journal of immunology.

[72]  Aled Clayton,et al.  Cancer exosomes trigger fibroblast to myofibroblast differentiation. , 2010, Cancer research.

[73]  Y. Zeng,et al.  The density of macrophages in the invasive front is inversely correlated to liver metastasis in colon cancer , 2010, Journal of Translational Medicine.

[74]  Carmen Visus,et al.  Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes1 , 2009, The Journal of Immunology.

[75]  R. Kerbel,et al.  Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR , 2009, Proceedings of the National Academy of Sciences.

[76]  Johan Skog,et al.  Glioblastoma microvesicles transport RNA and protein that promote tumor growth and provide diagnostic biomarkers , 2008, Nature Cell Biology.

[77]  A. Guha,et al.  Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells , 2008, Nature Cell Biology.

[78]  Y. Shaul,et al.  Yap1 phosphorylation by c-Abl is a critical step in selective activation of proapoptotic genes in response to DNA damage. , 2008, Molecular cell.

[79]  T. Hagemann,et al.  The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. , 2007, Cancer research.

[80]  S. Akira,et al.  Macrophage/Cancer Cell Interactions Mediate Hormone Resistance by a Nuclear Receptor Derepression Pathway , 2006, Cell.

[81]  N. Tapon,et al.  The Salvador partner Hippo promotes apoptosis and cell-cycle exit in Drosophila , 2003, Nature Cell Biology.

[82]  R. Deshaies,et al.  Protacs: Chimeric molecules that target proteins to the Skp1–Cullin–F box complex for ubiquitination and degradation , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[83]  N. Kaliss.  Immunological enhancement of tumor homografts in mice: a review. , 1958, Cancer research.

[84]  L. Chin,et al.  Targeting YAP-Dependent MDSC Infiltration Impairs Tumor Progression. , 2016, Cancer discovery.

[85]  J. Pollard.  Tumour-educated macrophages promote tumour progression and metastasis , 2004, Nature Reviews Cancer.

[86]  J. Downward,et al.  Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. , 2003, Molecular cell.